Citigroup Inc. Purchases 138,378 Shares of Moderna, Inc. (NASDAQ:MRNA)

Citigroup Inc. grew its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 30.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 591,910 shares of the company's stock after purchasing an additional 138,378 shares during the period. Citigroup Inc. owned about 0.15% of Moderna worth $39,557,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna in the 2nd quarter valued at approximately $26,000. Family Firm Inc. purchased a new position in Moderna in the second quarter valued at $33,000. Bank & Trust Co acquired a new position in shares of Moderna during the second quarter worth about $36,000. Hanseatic Management Services Inc. acquired a new stake in shares of Moderna in the 2nd quarter valued at $48,000. Finally, Plato Investment Management Ltd lifted its holdings in Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock worth $49,000 after buying an additional 288 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. HSBC upgraded Moderna from a "hold" rating to a "buy" rating and set a $58.00 target price on the stock in a research report on Monday, November 18th. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a report on Friday, November 8th. Leerink Partners cut their price target on Moderna from $60.00 to $48.00 and set an "underperform" rating for the company in a research note on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a "sell" rating to a "hold" rating and reduced their price objective for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Sanford C. Bernstein assumed coverage on Moderna in a report on Thursday, October 17th. They set a "market perform" rating and a $55.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $84.00.

Moderna Trading Up 6.2 %

Shares of Moderna stock traded up $2.55 during trading hours on Monday, hitting $43.66. The company's stock had a trading volume of 15,748,358 shares, compared to its average volume of 4,886,862. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The stock has a 50 day moving average of $54.96 and a 200 day moving average of $93.71. The company has a market capitalization of $16.80 billion, a PE ratio of -7.66 and a beta of 1.69.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the company posted ($1.39) earnings per share. Moderna's revenue was up 3.8% on a year-over-year basis. Analysts predict that Moderna, Inc. will post -9.44 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 2,930 shares of company stock valued at $217,170. 15.20% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.